Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgolide B Injection in Healthy Participants
NCT07457008Phase 1Completed
- Sponsor
- West China Second University Hospital
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ginkgolide b in ischemic stroke (4 arms), sponsored by West China Second University Hospital. Primary endpoints: Incidence of Adverse Events at Day 15, Number of Participants with Clinically Significant Changes in Laboratory Parameters at Day 15 and 1 more. Started Jul 2021; status: completed.
02
Drugs
ginkgolide b
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07457008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457008.